Pipeline
Kayothera is advancing first-in-class oral small molecules across cardiometabolic disease, obesity, and reproductive health.
Pipeline
Three programs connected by one upstream biological foundation.
Current development focus
Designed to inhibit retinoid synthesis in tissues relevant to type 2 diabetes and cardiometabolic disease, with a development focus on beta-cell function and metabolic health.
Current development focus
Designed to target rexinoid pathway biology tied to thyroid function, mitochondrial function, adipogenesis, and energy expenditure.
Current development focus
Designed to inhibit ALDH1a2-mediated retinoic acid synthesis in reproductive biology, with relevance to spermatogenesis and male contraceptive development.
| Program | Disease area | Pathway relevance |
|---|---|---|
| KAYO-1732 | Type 2 diabetes / cardiometabolic disease | Retinoid synthesis / ALDH1a3-related biology |
| KAYO-2000 | Obesity | Rexinoid pathway / ALDH1a1-related biology |
| KAYO-1609 | Male contraceptive / reproductive health | ALDH1a2 / retinoic acid synthesis / Sertoli cells |
Development status
A compact view of the original stage structure across Kayothera’s three programs.
Relative progress reflects Kayothera’s original Science-page pipeline chart and remains subject to client confirmation, study outcomes, regulatory feedback, funding, and company strategy.
Program details
Program descriptions reflect current public positioning. Exact future stages and timing remain subject to study outcomes and company strategy.
Type 2 diabetes / cardiometabolic disease
Designed to inhibit retinoid synthesis in tissues relevant to type 2 diabetes and cardiometabolic disease, with a development focus on beta-cell function and metabolic health.
Development candidate nominated for type 2 diabetes and cardiometabolic indications.
Obesity
Designed to target rexinoid pathway biology tied to thyroid function, mitochondrial function, adipogenesis, and energy expenditure.
Advancing an oral small-molecule approach for obesity-related pathway biology.
Male contraceptive / reproductive health
Designed to inhibit ALDH1a2-mediated retinoic acid synthesis in reproductive biology, with relevance to spermatogenesis and male contraceptive development.
Exploring pathway-selective inhibition in reproductive health.
Connect with Kayothera